ENTA
NASDAQ · Biotechnology
Enanta Pharmaceuticals Inc
$12.51
-0.49 (-3.77%)
Open$13.00
Previous Close$13.00
Day High$13.19
Day Low$12.44
52W High$17.15
52W Low$4.09
Volume—
Avg Volume161.1K
Market Cap382.77M
P/E Ratio—
EPS$-3.20
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+256.1% upside
Current
$12.51
$12.51
Target
$44.55
$44.55
$33.16
$44.55 avg
$53.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 90.78M | 99.57M | 75.01M |
| Net Income | -113,794,801 | -112,334,453 | -19,564,680 |
| Profit Margin | -125.4% | -119.1% | -26.1% |
| EBITDA | -112,229,348 | -116,944,039 | -21,379,947 |
| Free Cash Flow | — | — | -13,998,479 |
| Rev Growth | -8.8% | -8.8% | -3.9% |
| Debt/Equity | 2.21 | 2.21 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |